Insights
AI Drug Discovery Protein Design Is Quietly Rewriting Biotech Economics
AI-driven protein design is quietly compressing biotech’s most expensive bottleneck. My take on why that shrinks big pharma’s moat — and what it doesn’t fix.
AI-driven protein design is quietly compressing biotech’s most expensive bottleneck. My take on why that shrinks big pharma’s moat — and what it doesn’t fix.
India just let Amazon and Flipkart own inventory for exports, not domestic sales. Here’s why that narrow carve-out is a masterclass in regulatory sequencing, and what it means for European SMBs eyeing India or similar markets.
Tell us what you’re trying to grow, or what’s slowing you down. We’ll respond within 48 hours with a clear plan of action.
No commitment. No pitch deck. Just a direct conversation about what we can build together.